hu.MAP 2.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: HuMAP2_03589
Confidence: Medium
Proteins| Genename | Protein Name | Links |
|---|---|---|
| ABL1 | Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150) | UniProt NCBI |
| KRAS | GTPase KRas (K-Ras 2) (Ki-Ras) (c-K-ras) (c-Ki-ras) [Cleaved into: GTPase KRas, N-terminally processed] | UniProt NCBI |
| ABHD5 | 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (EC 2.3.1.51) (Abhydrolase domain-containing protein 5) (Lipid droplet-binding protein CGI-58) | UniProt NCBI |
| NRAS | GTPase NRas (Transforming protein N-Ras) | UniProt NCBI |
| HRAS | GTPase HRas (H-Ras-1) (Ha-Ras) (Transforming protein p21) (c-H-ras) (p21ras) [Cleaved into: GTPase HRas, N-terminally processed] | UniProt NCBI |
| RIN1 | Ras and Rab interactor 1 (Ras inhibitor JC99) (Ras interaction/interference protein 1) | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| HP:0010815 | 2.01819057829e-08 | 0.5 | NRAS KRAS HRAS | Nevus sebaceous |
| HP:0010817 | 2.01819057829e-08 | 0.5 | NRAS KRAS HRAS | Linear nevus sebaceous |
| REAC:R-HSA-6802953 | 2.3817666497e-08 | 0.5 | NRAS KRAS HRAS | RAS signaling downstream of NF1 loss-of-function variants |
| REAC:R-HSA-1169092 | 2.3817666497e-08 | 0.5 | NRAS KRAS HRAS | Activation of RAS in B cells |
| WP:WP4223 | 2.81367316211e-08 | 0.833333333333 | NRAS HRAS KRAS ABL1 RIN1 | Ras Signaling |
| KEGG:04014 | 7.49636621947e-08 | 0.833333333333 | NRAS HRAS KRAS ABL1 RIN1 | Ras signaling pathway |
| REAC:R-HSA-9634635 | 1.19052344835e-07 | 0.5 | NRAS KRAS HRAS | Estrogen-stimulated signaling through PRKCZ |
| REAC:R-HSA-2428933 | 1.19052344835e-07 | 0.5 | NRAS KRAS HRAS | SHC-related events triggered by IGF1R |
| REAC:R-HSA-9034864 | 1.19052344835e-07 | 0.5 | NRAS KRAS HRAS | Activated NTRK3 signals through RAS |
| REAC:R-HSA-9026519 | 1.19052344835e-07 | 0.5 | NRAS KRAS HRAS | Activated NTRK2 signals through RAS |
| REAC:R-HSA-112412 | 1.19052344835e-07 | 0.5 | NRAS KRAS HRAS | SOS-mediated signalling |
| HP:0010816 | 2.01758072203e-07 | 0.5 | NRAS KRAS HRAS | Epidermal nevus |
| REAC:R-HSA-2179392 | 2.08310119344e-07 | 0.5 | NRAS KRAS HRAS | EGFR Transactivation by Gastrin |
| REAC:R-HSA-179812 | 2.08310119344e-07 | 0.5 | NRAS KRAS HRAS | GRB2 events in EGFR signaling |
| WP:WP2290 | 3.29800460256e-07 | 0.5 | NRAS KRAS HRAS | RalA downstream regulated genes |
| REAC:R-HSA-9028731 | 3.33245821776e-07 | 0.5 | NRAS KRAS HRAS | Activated NTRK2 signals through FRS2 and FRS3 |
| REAC:R-HSA-180336 | 3.33245821776e-07 | 0.5 | NRAS KRAS HRAS | SHC1 events in EGFR signaling |
| REAC:R-HSA-5654704 | 3.33245821776e-07 | 0.5 | NRAS KRAS HRAS | SHC-mediated cascade:FGFR3 |
| KEGG:05220 | 3.86936610311e-07 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Chronic myeloid leukemia |
| REAC:R-HSA-1250347 | 4.99793187022e-07 | 0.5 | NRAS KRAS HRAS | SHC1 events in ERBB4 signaling |
| REAC:R-HSA-8851805 | 4.99793187022e-07 | 0.5 | NRAS KRAS HRAS | MET activates RAS signaling |
| REAC:R-HSA-8853334 | 4.99793187022e-07 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR3 fusions in cancer |
| KEGG:04012 | 5.04993971524e-07 | 0.666666666667 | NRAS HRAS ABL1 KRAS | ErbB signaling pathway |
| WP:WP673 | 6.07026408583e-07 | 0.666666666667 | NRAS HRAS ABL1 KRAS | ErbB Signaling Pathway |
| REAC:R-HSA-5654706 | 7.13882356429e-07 | 0.5 | NRAS KRAS HRAS | FRS-mediated FGFR3 signaling |
| REAC:R-HSA-5655291 | 7.13882356429e-07 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR4 in disease |
| REAC:R-HSA-1963640 | 7.13882356429e-07 | 0.5 | NRAS KRAS HRAS | GRB2 events in ERBB2 signaling |
| REAC:R-HSA-5654719 | 9.81439878764e-07 | 0.5 | NRAS KRAS HRAS | SHC-mediated cascade:FGFR4 |
| REAC:R-HSA-5654688 | 9.81439878764e-07 | 0.5 | NRAS KRAS HRAS | SHC-mediated cascade:FGFR1 |
| HP:0001528 | 1.12933306268e-06 | 0.5 | NRAS KRAS HRAS | Hemihypertrophy |
| WP:WP4301 | 1.22215075874e-06 | 0.5 | NRAS KRAS HRAS | Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells |
| REAC:R-HSA-171007 | 1.30838871118e-06 | 0.5 | NRAS KRAS HRAS | p38MAPK events |
| REAC:R-HSA-5654699 | 1.30838871118e-06 | 0.5 | NRAS KRAS HRAS | SHC-mediated cascade:FGFR2 |
| WP:WP710 | 1.37568401472e-06 | 0.666666666667 | NRAS HRAS ABL1 KRAS | DNA Damage Response (only ATM dependent) |
| HP:0001442 | 1.69374357824e-06 | 0.5 | NRAS KRAS HRAS | Somatic mosaicism |
| REAC:R-HSA-5654712 | 1.70064822019e-06 | 0.5 | NRAS KRAS HRAS | FRS-mediated FGFR4 signaling |
| REAC:R-HSA-9027284 | 1.70064822019e-06 | 0.5 | NRAS KRAS HRAS | Erythropoietin activates RAS |
| REAC:R-HSA-8849471 | 1.70064822019e-06 | 0.5 | NRAS KRAS HRAS | PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases |
| REAC:R-HSA-5654693 | 1.70064822019e-06 | 0.5 | NRAS KRAS HRAS | FRS-mediated FGFR1 signaling |
| REAC:R-HSA-5637812 | 1.70064822019e-06 | 0.5 | NRAS KRAS HRAS | Signaling by EGFRvIII in Cancer |
| REAC:R-HSA-5637810 | 1.70064822019e-06 | 0.5 | NRAS KRAS HRAS | Constitutive Signaling by EGFRvIII |
| WP:WP732 | 1.70690021658e-06 | 0.5 | NRAS KRAS HRAS | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling |
| KEGG:04722 | 1.72925777609e-06 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Neurotrophin signaling pathway |
| HP:0001680 | 1.83958904886e-06 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Coarctation of aorta |
| REAC:R-HSA-5655332 | 2.16413418261e-06 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR3 in disease |
| REAC:R-HSA-8853338 | 2.16413418261e-06 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR3 point mutants in cancer |
| REAC:R-HSA-5654700 | 2.16413418261e-06 | 0.5 | NRAS KRAS HRAS | FRS-mediated FGFR2 signaling |
| REAC:R-HSA-9034015 | 2.16413418261e-06 | 0.5 | NRAS KRAS HRAS | Signaling by NTRK3 (TRKC) |
| REAC:R-HSA-5654708 | 2.16413418261e-06 | 0.5 | NRAS KRAS HRAS | Downstream signaling of activated FGFR3 |
| REAC:R-HSA-210993 | 2.70475878656e-06 | 0.5 | NRAS KRAS HRAS | Tie2 Signaling |
| REAC:R-HSA-1250196 | 2.70475878656e-06 | 0.5 | NRAS KRAS HRAS | SHC1 events in ERBB2 signaling |
| HP:0007206 | 3.32599070026e-06 | 0.5 | NRAS KRAS HRAS | Hemimegalencephaly |
| REAC:R-HSA-5218921 | 3.32843063241e-06 | 0.5 | NRAS KRAS HRAS | VEGFR2 mediated cell proliferation |
| REAC:R-HSA-881907 | 3.32843063241e-06 | 0.5 | NRAS KRAS HRAS | Gastrin-CREB signalling pathway via PKC and MAPK |
| WP:WP2870 | 3.44114296401e-06 | 0.5 | NRAS KRAS HRAS | Extracellular vesicle-mediated signaling in recipient cells |
| REAC:R-HSA-5654716 | 4.04105473372e-06 | 0.5 | NRAS KRAS HRAS | Downstream signaling of activated FGFR4 |
| REAC:R-HSA-1236382 | 4.04105473372e-06 | 0.5 | NRAS KRAS HRAS | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants |
| REAC:R-HSA-167044 | 4.04105473372e-06 | 0.5 | NRAS KRAS HRAS | Signalling to RAS |
| REAC:R-HSA-5637815 | 4.04105473372e-06 | 0.5 | NRAS KRAS HRAS | Signaling by Ligand-Responsive EGFR Variants in Cancer |
| HP:0000267 | 4.43398396567e-06 | 0.5 | NRAS KRAS HRAS | Cranial asymmetry |
| REAC:R-HSA-442982 | 4.84853251826e-06 | 0.5 | NRAS KRAS HRAS | Ras activation upon Ca2+ influx through NMDA receptor |
| REAC:R-HSA-5654696 | 4.84853251826e-06 | 0.5 | NRAS KRAS HRAS | Downstream signaling of activated FGFR2 |
| WP:WP2643 | 4.89916083633e-06 | 0.5 | NRAS KRAS HRAS | Nanoparticle-mediated activation of receptor signaling |
| REAC:R-HSA-1643713 | 5.75676182894e-06 | 0.5 | NRAS KRAS HRAS | Signaling by EGFR in Cancer |
| WP:WP3844 | 6.06977286255e-06 | 0.5 | NRAS KRAS HRAS | PI3K-AKT-mTOR signaling pathway and therapeutic opportunities |
| REAC:R-HSA-9006115 | 6.77163692478e-06 | 0.5 | NRAS KRAS HRAS | Signaling by NTRK2 (TRKB) |
| REAC:R-HSA-5654687 | 6.77163692478e-06 | 0.5 | NRAS KRAS HRAS | Downstream signaling of activated FGFR1 |
| HP:0004912 | 7.33401028552e-06 | 0.5 | NRAS KRAS HRAS | Hypophosphatemic rickets |
| WP:WP3676 | 7.41304562138e-06 | 0.5 | NRAS KRAS HRAS | BDNF-TrkB Signaling |
| WP:WP437 | 7.8193322942e-06 | 0.666666666667 | HRAS KRAS ABL1 RIN1 | EGF/EGFR Signaling Pathway |
| REAC:R-HSA-2424491 | 7.89904848188e-06 | 0.5 | NRAS KRAS HRAS | DAP12 signaling |
| REAC:R-HSA-5621575 | 7.89904848188e-06 | 0.5 | NRAS KRAS HRAS | CD209 (DC-SIGN) signaling |
| KEGG:05206 | 8.11848952866e-06 | 0.666666666667 | NRAS HRAS ABL1 KRAS | MicroRNAs in cancer |
| WP:WP422 | 8.15311651655e-06 | 0.5 | NRAS KRAS HRAS | MAPK Cascade |
| KEGG:04360 | 9.9140838705e-06 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Axon guidance |
| REAC:R-HSA-9006335 | 1.05150257754e-05 | 0.5 | NRAS KRAS HRAS | Signaling by Erythropoietin |
| WP:WP2828 | 1.06647420214e-05 | 0.5 | NRAS KRAS HRAS | Bladder Cancer |
| HP:0011073 | 1.12796815876e-05 | 0.5 | NRAS KRAS HRAS | Abnormality of dental color |
| REAC:R-HSA-2172127 | 1.20153549581e-05 | 0.5 | NRAS KRAS HRAS | DAP12 interactions |
| KEGG:05219 | 1.30007694159e-05 | 0.5 | NRAS KRAS HRAS | Bladder cancer |
| KEGG:05216 | 1.30007694159e-05 | 0.5 | NRAS KRAS HRAS | Thyroid cancer |
| REAC:R-HSA-2871796 | 1.54300761667e-05 | 0.5 | NRAS KRAS HRAS | FCERI mediated MAPK activation |
| REAC:R-HSA-442742 | 1.54300761667e-05 | 0.5 | NRAS KRAS HRAS | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling |
| HP:0009720 | 1.64311379786e-05 | 0.5 | NRAS KRAS HRAS | Adenoma sebaceum |
| HP:0001548 | 1.64311379786e-05 | 0.5 | NRAS KRAS HRAS | Overgrowth |
| WP:WP2586 | 1.7131668569e-05 | 0.5 | NRAS KRAS HRAS | Aryl Hydrocarbon Receptor |
| REAC:R-HSA-186763 | 1.73562101673e-05 | 0.5 | NRAS KRAS HRAS | Downstream signal transduction |
| REAC:R-HSA-5654741 | 1.94360151212e-05 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR3 |
| WP:WP4535 | 1.97581132023e-05 | 0.5 | NRAS KRAS HRAS | Envelope proteins and their potential roles in EDMD physiopathology |
| REAC:R-HSA-5673000 | 2.16753530756e-05 | 0.5 | NRAS KRAS HRAS | RAF activation |
| REAC:R-HSA-187687 | 2.16753530756e-05 | 0.5 | NRAS KRAS HRAS | Signalling to ERKs |
| HP:0000337 | 2.23653016197e-05 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Broad forehead |
| HP:0006740 | 2.2948325134e-05 | 0.5 | NRAS KRAS HRAS | Transitional cell carcinoma of the bladder |
| REAC:R-HSA-5654743 | 2.40800825039e-05 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR4 |
| WP:WP4539 | 2.41794273383e-05 | 0.5 | NRAS KRAS HRAS | Synaptic signaling pathways associated with autism spectrum disorder |
| CORUM:1700 | 2.51655344529e-05 | 0.333333333333 | RIN1 HRAS | ABL2-HRAS-RIN1 complex |
| REAC:R-HSA-112399 | 2.6656058306e-05 | 0.5 | NRAS KRAS HRAS | IRS-mediated signalling |
| REAC:R-HSA-5655302 | 2.6656058306e-05 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR1 in disease |
| HP:0002212 | 2.6768997633e-05 | 0.5 | NRAS KRAS HRAS | Curly hair |
| HP:0001355 | 3.09909944032e-05 | 0.5 | NRAS KRAS HRAS | Megalencephaly |
| HP:0002862 | 3.09909944032e-05 | 0.5 | NRAS KRAS HRAS | Bladder carcinoma |
| HP:0010615 | 3.09909944032e-05 | 0.5 | NRAS KRAS HRAS | Angiofibromas |
| REAC:R-HSA-5655253 | 3.54699593753e-05 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR2 in disease |
| REAC:R-HSA-2428928 | 3.54699593753e-05 | 0.5 | NRAS KRAS HRAS | IRS-related events triggered by IGF1R |
| REAC:R-HSA-2428924 | 3.54699593753e-05 | 0.5 | NRAS KRAS HRAS | IGF1R signaling cascade |
| HP:0002816 | 3.56342540167e-05 | 0.5 | NRAS KRAS HRAS | Genu recurvatum |
| HP:0009725 | 3.56342540167e-05 | 0.5 | NRAS KRAS HRAS | Bladder neoplasm |
| HP:0008064 | 3.7653275253e-05 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Ichthyosis |
| REAC:R-HSA-2404192 | 3.878939824e-05 | 0.5 | NRAS KRAS HRAS | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
| REAC:R-HSA-1433557 | 3.878939824e-05 | 0.5 | NRAS KRAS HRAS | Signaling by SCF-KIT |
| KEGG:04730 | 3.91015753854e-05 | 0.5 | NRAS KRAS HRAS | Long-term depression |
| HP:0010500 | 4.07187029137e-05 | 0.5 | NRAS KRAS HRAS | Hyperextensibility of the knee |
| HP:0001048 | 4.07187029137e-05 | 0.5 | NRAS KRAS HRAS | Cavernous hemangioma |
| KEGG:04929 | 4.13953986709e-05 | 0.5 | NRAS KRAS HRAS | GnRH secretion |
| REAC:R-HSA-74751 | 4.23093044129e-05 | 0.5 | NRAS KRAS HRAS | Insulin receptor signalling cascade |
| REAC:R-HSA-5654736 | 4.23093044129e-05 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR1 |
| REAC:R-HSA-6802948 | 4.23093044129e-05 | 0.5 | NRAS KRAS HRAS | Signaling by high-kinase activity BRAF mutants |
| WP:WP4205 | 4.35658034931e-05 | 0.5 | NRAS KRAS HRAS | MET in type 1 papillary renal cell carcinoma |
| KEGG:04664 | 4.37769643831e-05 | 0.5 | NRAS KRAS HRAS | Fc epsilon RI signaling pathway |
| KEGG:04370 | 4.37769643831e-05 | 0.5 | NRAS KRAS HRAS | VEGF signaling pathway |
| REAC:R-HSA-5675221 | 4.60355113742e-05 | 0.5 | NRAS KRAS HRAS | Negative regulation of MAPK pathway |
| KEGG:04213 | 4.62479008493e-05 | 0.5 | NRAS KRAS HRAS | Longevity regulating pathway - multiple species |
| HP:0002132 | 4.6264255405e-05 | 0.5 | NRAS KRAS HRAS | Porencephalic cyst |
| KEGG:05213 | 4.88098353951e-05 | 0.5 | NRAS KRAS HRAS | Endometrial cancer |
| WP:WP4155 | 5.62683263201e-05 | 0.5 | NRAS KRAS HRAS | Endometrial cancer |
| KEGG:05221 | 5.70578857394e-05 | 0.5 | NRAS KRAS HRAS | Acute myeloid leukemia |
| REAC:R-HSA-5674135 | 5.85102183028e-05 | 0.5 | NRAS KRAS HRAS | MAP2K and MAPK activation |
| WP:WP4341 | 5.90727924684e-05 | 0.5 | NRAS KRAS HRAS | Non-genomic actions of 1,25 dihydroxyvitamin D3 |
| KEGG:04720 | 6.30413655994e-05 | 0.5 | NRAS KRAS HRAS | Long-term potentiation |
| KEGG:04137 | 6.30413655994e-05 | 0.5 | NRAS KRAS HRAS | Mitophagy - animal |
| KEGG:04917 | 6.30413655994e-05 | 0.5 | NRAS KRAS HRAS | Prolactin signaling pathway |
| KEGG:05218 | 6.30413655994e-05 | 0.5 | NRAS KRAS HRAS | Melanoma |
| WP:WP3303 | 6.49572615844e-05 | 0.5 | NRAS KRAS HRAS | RAC1/PAK1/p38/MMP2 Pathway |
| HP:0001428 | 6.50332428373e-05 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Somatic mutation |
| KEGG:05211 | 6.61834063766e-05 | 0.5 | NRAS KRAS HRAS | Renal cell carcinoma |
| REAC:R-HSA-1227986 | 6.79649802247e-05 | 0.5 | NRAS KRAS HRAS | Signaling by ERBB2 |
| KEGG:05223 | 6.94278084771e-05 | 0.5 | NRAS KRAS HRAS | Non-small cell lung cancer |
| REAC:R-HSA-177929 | 7.30512953501e-05 | 0.5 | NRAS KRAS HRAS | Signaling by EGFR |
| HP:0003109 | 7.34553632007e-05 | 0.5 | NRAS KRAS HRAS | Hyperphosphaturia |
| HP:0025510 | 7.51372352298e-05 | 0.333333333333 | NRAS HRAS | Nevus spilus |
| HP:0005600 | 7.51372352298e-05 | 0.333333333333 | NRAS HRAS | Congenital giant melanocytic nevus |
| REAC:R-HSA-6802955 | 7.83846458188e-05 | 0.5 | NRAS KRAS HRAS | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| REAC:R-HSA-6802946 | 7.83846458188e-05 | 0.5 | NRAS KRAS HRAS | Signaling by moderate kinase activity BRAF mutants |
| KEGG:04662 | 7.9791370908e-05 | 0.5 | NRAS KRAS HRAS | B cell receptor signaling pathway |
| KEGG:05230 | 7.9791370908e-05 | 0.5 | NRAS KRAS HRAS | Central carbon metabolism in cancer |
| WP:WP4255 | 8.13431193589e-05 | 0.5 | NRAS KRAS HRAS | Non-small cell lung cancer |
| HP:0002748 | 8.1604724041e-05 | 0.5 | NRAS KRAS HRAS | Rickets |
| KEGG:05214 | 8.34614014946e-05 | 0.5 | NRAS KRAS HRAS | Glioma |
| HP:0001596 | 8.78154986054e-05 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Alopecia |
| REAC:R-HSA-1236394 | 8.98156691281e-05 | 0.5 | NRAS KRAS HRAS | Signaling by ERBB4 |
| REAC:R-HSA-8848021 | 8.98156691281e-05 | 0.5 | NRAS KRAS HRAS | Signaling by PTK6 |
| REAC:R-HSA-9006927 | 8.98156691281e-05 | 0.5 | NRAS KRAS HRAS | Signaling by Non-Receptor Tyrosine Kinases |
| HP:0012599 | 9.96642800208e-05 | 0.5 | NRAS KRAS HRAS | Abnormal urine phosphate concentration |
| KEGG:01521 | 0.000107857457806 | 0.5 | NRAS KRAS HRAS | EGFR tyrosine kinase inhibitor resistance |
| REAC:R-HSA-375165 | 0.000115897320389 | 0.5 | NRAS KRAS HRAS | NCAM signaling for neurite out-growth |
| WP:WP2261 | 0.000131360147496 | 0.5 | NRAS KRAS HRAS | Signaling Pathways in Glioblastoma |
| HP:0100555 | 0.000131452960702 | 0.5 | NRAS KRAS HRAS | Asymmetric growth |
| KEGG:05235 | 0.000136577689714 | 0.5 | NRAS KRAS HRAS | PD-L1 expression and PD-1 checkpoint pathway in cancer |
| REAC:R-HSA-1226099 | 0.00013845803743 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR in disease |
| KEGG:04912 | 0.000141809175237 | 0.5 | NRAS KRAS HRAS | GnRH signaling pathway |
| REAC:R-HSA-186797 | 0.000146580428081 | 0.5 | NRAS KRAS HRAS | Signaling by PDGF |
| KEGG:05210 | 0.000147172017102 | 0.5 | NRAS KRAS HRAS | Colorectal cancer |
| KEGG:04211 | 0.000147172017102 | 0.5 | NRAS KRAS HRAS | Longevity regulating pathway |
| HP:0002148 | 0.00015600923299 | 0.5 | NRAS KRAS HRAS | Hypophosphatemia |
| WP:WP35 | 0.000157102141644 | 0.5 | NRAS KRAS HRAS | G Protein Signaling Pathways |
| KEGG:04540 | 0.000158298174337 | 0.5 | NRAS KRAS HRAS | Gap junction |
| WP:WP231 | 0.00016262225713 | 0.5 | NRAS KRAS HRAS | TNF alpha Signaling Pathway |
| REAC:R-HSA-6802949 | 0.000163763058745 | 0.5 | NRAS KRAS HRAS | Signaling by RAS mutants |
| KEGG:04625 | 0.000182197158451 | 0.5 | NRAS KRAS HRAS | C-type lectin receptor signaling pathway |
| REAC:R-HSA-5654738 | 0.000182234576694 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR2 |
| KEGG:04916 | 0.000188524277315 | 0.5 | NRAS KRAS HRAS | Melanogenesis |
| KEGG:05231 | 0.000188524277315 | 0.5 | NRAS KRAS HRAS | Choline metabolism in cancer |
| REAC:R-HSA-74752 | 0.000191968063148 | 0.5 | NRAS KRAS HRAS | Signaling by Insulin receptor |
| KEGG:05215 | 0.000194995535624 | 0.5 | NRAS KRAS HRAS | Prostate cancer |
| KEGG:01522 | 0.000194995535624 | 0.5 | NRAS KRAS HRAS | Endocrine resistance |
| KEGG:04660 | 0.000194995535624 | 0.5 | NRAS KRAS HRAS | T cell receptor signaling pathway |
| KEGG:04933 | 0.000201612526794 | 0.5 | NRAS KRAS HRAS | AGE-RAGE signaling pathway in diabetic complications |
| KEGG:04726 | 0.000229569653691 | 0.5 | NRAS KRAS HRAS | Serotonergic synapse |
| REAC:R-HSA-6802952 | 0.000234354357006 | 0.5 | NRAS KRAS HRAS | Signaling by BRAF and RAF fusions |
| KEGG:04725 | 0.000236939175691 | 0.5 | NRAS KRAS HRAS | Cholinergic synapse |
| WP:WP4321 | 0.000239193980725 | 0.5 | NRAS KRAS HRAS | Thermogenesis |
| HP:0000269 | 0.000247562723131 | 0.5 | NRAS KRAS HRAS | Prominent occiput |
| WP:WP4541 | 0.000253909359144 | 0.5 | NRAS KRAS HRAS | Hippo-Merlin Signaling Dysregulation |
| KEGG:04650 | 0.000259985721773 | 0.5 | NRAS KRAS HRAS | Natural killer cell mediated cytotoxicity |
| HP:0001679 | 0.000267973034972 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal aortic morphology |
| REAC:R-HSA-9009391 | 0.000269929792646 | 0.5 | NRAS KRAS HRAS | Extra-nuclear estrogen signaling |
| REAC:R-HSA-190236 | 0.00028253993633 | 0.5 | NRAS KRAS HRAS | Signaling by FGFR |
| REAC:R-HSA-5658442 | 0.00028253993633 | 0.5 | NRAS KRAS HRAS | Regulation of RAS by GAPs |
| HP:0002671 | 0.000304375323156 | 0.5 | NRAS KRAS HRAS | Basal cell carcinoma |
| HP:0000995 | 0.000325078967548 | 0.5 | NRAS KRAS HRAS | Melanocytic nevus |
| HP:0000085 | 0.000325078967548 | 0.5 | NRAS KRAS HRAS | Horseshoe kidney |
| HP:0000178 | 0.000331404976924 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormality of lower lip |
| HP:0100529 | 0.000346698404585 | 0.5 | NRAS KRAS HRAS | Abnormal blood phosphate concentration |
| KEGG:04071 | 0.000347449247485 | 0.5 | NRAS KRAS HRAS | Sphingolipid signaling pathway |
| REAC:R-HSA-438064 | 0.00036649373235 | 0.5 | NRAS KRAS HRAS | Post NMDA receptor activation events |
| REAC:R-HSA-6806834 | 0.00036649373235 | 0.5 | NRAS KRAS HRAS | Signaling by MET |
| REAC:R-HSA-187037 | 0.00036649373235 | 0.5 | NRAS KRAS HRAS | Signaling by NTRK1 (TRKA) |
| HP:0100625 | 0.000369253258459 | 0.5 | NRAS KRAS HRAS | Enlarged thorax |
| KEGG:04919 | 0.000387269280812 | 0.5 | NRAS KRAS HRAS | Thyroid hormone signaling pathway |
| KEGG:04068 | 0.000397675631396 | 0.5 | NRAS KRAS HRAS | FoxO signaling pathway |
| HP:0000474 | 0.000417247653264 | 0.5 | NRAS KRAS HRAS | Thickened nuchal skin fold |
| HP:0010614 | 0.000417247653264 | 0.5 | NRAS KRAS HRAS | Fibroma |
| REAC:R-HSA-1168372 | 0.000430779573811 | 0.5 | NRAS KRAS HRAS | Downstream signaling events of B Cell Receptor (BCR) |
| HP:0003196 | 0.000442885347641 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Short nose |
| REAC:R-HSA-6802957 | 0.000447942844044 | 0.5 | NRAS KRAS HRAS | Oncogenic MAPK signaling |
| HP:0010759 | 0.00045066196833 | 0.333333333333 | NRAS HRAS | Prominence of the premaxilla |
| WP:WP3929 | 0.000457080919886 | 0.5 | NRAS KRAS HRAS | Chemokine signaling pathway |
| KEGG:04926 | 0.000464025836468 | 0.5 | NRAS KRAS HRAS | Relaxin signaling pathway |
| HP:0001911 | 0.00046656087189 | 0.666666666667 | NRAS ABHD5 ABL1 KRAS | Abnormal granulocyte morphology |
| HP:0012316 | 0.000469218904624 | 0.5 | NRAS KRAS HRAS | Fibrous tissue neoplasm |
| KEGG:04915 | 0.00048767047927 | 0.5 | NRAS KRAS HRAS | Estrogen signaling pathway |
| KEGG:04550 | 0.000499786319182 | 0.5 | NRAS KRAS HRAS | Signaling pathways regulating pluripotency of stem cells |
| KEGG:04371 | 0.000512099919502 | 0.5 | NRAS KRAS HRAS | Apelin signaling pathway |
| KEGG:04210 | 0.000524612840052 | 0.5 | NRAS KRAS HRAS | Apoptosis |
| KEGG:04910 | 0.000524612840052 | 0.5 | NRAS KRAS HRAS | Insulin signaling pathway |
| KEGG:04072 | 0.000537326639668 | 0.5 | NRAS KRAS HRAS | Phospholipase D signaling pathway |
| REAC:R-HSA-442755 | 0.000560531240275 | 0.5 | NRAS KRAS HRAS | Activation of NMDA receptors and postsynaptic events |
| HP:0011061 | 0.000561533098737 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormality of dental structure |
| HP:0100031 | 0.000585718024741 | 0.5 | NRAS KRAS HRAS | Neoplasm of the thyroid gland |
| KEGG:04062 | 0.000590221771159 | 0.5 | NRAS KRAS HRAS | Chemokine signaling pathway |
| KEGG:05224 | 0.000590221771159 | 0.5 | NRAS KRAS HRAS | Breast cancer |
| KEGG:05226 | 0.000603963314278 | 0.5 | NRAS KRAS HRAS | Gastric cancer |
| HP:0002861 | 0.000617572732129 | 0.5 | NRAS KRAS HRAS | Melanoma |
| KEGG:05200 | 0.000619708787865 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Pathways in cancer |
| KEGG:04140 | 0.000632078586851 | 0.5 | NRAS KRAS HRAS | Autophagy - animal |
| HP:0010974 | 0.000639163727168 | 0.666666666667 | NRAS ABHD5 ABL1 KRAS | Abnormal myeloid leukocyte morphology |
| WP:WP4262 | 0.000644066937114 | 0.5 | NRAS KRAS HRAS | Breast cancer pathway |
| HP:0001357 | 0.000650558436223 | 0.5 | NRAS KRAS HRAS | Plagiocephaly |
| KEGG:04921 | 0.000661047116041 | 0.5 | NRAS KRAS HRAS | Oxytocin signaling pathway |
| KEGG:05160 | 0.000675855226254 | 0.5 | NRAS KRAS HRAS | Hepatitis C |
| HP:0004422 | 0.000684694628873 | 0.5 | NRAS KRAS HRAS | Biparietal narrowing |
| REAC:R-HSA-166520 | 0.000713906652255 | 0.5 | NRAS KRAS HRAS | Signaling by NTRKs |
| REAC:R-HSA-4420097 | 0.000713906652255 | 0.5 | NRAS KRAS HRAS | VEGFA-VEGFR2 Pathway |
| WP:WP4666 | 0.000731117090022 | 0.5 | NRAS KRAS HRAS | Hepatitis B infection |
| HP:0030886 | 0.000750968775169 | 0.333333333333 | NRAS KRAS | Abnormal lymphocyte apoptosis |
| HP:0002731 | 0.000750968775169 | 0.333333333333 | NRAS KRAS | Decreased lymphocyte apoptosis |
| KEGG:04150 | 0.000802296549804 | 0.5 | NRAS KRAS HRAS | mTOR signaling pathway |
| KEGG:04218 | 0.000819121924932 | 0.5 | NRAS KRAS HRAS | Cellular senescence |
| HP:0011425 | 0.000914762075078 | 0.5 | NRAS KRAS HRAS | Fetal ultrasound soft marker |
| REAC:R-HSA-194138 | 0.000920605178739 | 0.5 | NRAS KRAS HRAS | Signaling by VEGF |
| REAC:R-HSA-983705 | 0.000977834083021 | 0.5 | NRAS KRAS HRAS | Signaling by the B Cell Receptor (BCR) |
| KEGG:05161 | 0.00100038089965 | 0.5 | NRAS KRAS HRAS | Hepatitis B |
| REAC:R-HSA-202733 | 0.00100731253956 | 0.5 | NRAS KRAS HRAS | Cell surface interactions at the vascular wall |
| KEGG:05225 | 0.00107971996751 | 0.5 | NRAS KRAS HRAS | Hepatocellular carcinoma |
| HP:0040198 | 0.00112625143517 | 0.333333333333 | NRAS HRAS | Non-medullary thyroid carcinoma |
| HP:0012209 | 0.00112625143517 | 0.333333333333 | NRAS KRAS | Juvenile myelomonocytic leukemia |
| HP:0001054 | 0.00112625143517 | 0.333333333333 | NRAS HRAS | Numerous nevi |
| KEGG:05167 | 0.00120635789569 | 0.5 | NRAS KRAS HRAS | Kaposi sarcoma-associated herpesvirus infection |
| KEGG:05034 | 0.00122837384883 | 0.5 | NRAS KRAS HRAS | Alcoholism |
| KEGG:04015 | 0.0013899609933 | 0.5 | NRAS KRAS HRAS | Rap1 signaling pathway |
| HP:0012311 | 0.0015764696333 | 0.333333333333 | NRAS KRAS | Monocytosis |
| HP:0010758 | 0.0015764696333 | 0.333333333333 | NRAS HRAS | Abnormality of the premaxilla |
| HP:0004097 | 0.00160229059062 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Deviation of finger |
| HP:0001642 | 0.00163893227657 | 0.5 | NRAS KRAS HRAS | Pulmonic stenosis |
| HP:0012591 | 0.00163893227657 | 0.5 | NRAS KRAS HRAS | Abnormal urinary electrolyte concentration |
| HP:0011217 | 0.00163893227657 | 0.5 | NRAS KRAS HRAS | Abnormal shape of the occiput |
| HP:0000465 | 0.00163893227657 | 0.5 | NRAS KRAS HRAS | Webbed neck |
| REAC:R-HSA-2454202 | 0.00164310787995 | 0.5 | NRAS KRAS HRAS | Fc epsilon receptor (FCERI) signaling |
| HP:0011368 | 0.00168463944601 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Epidermal thickening |
| KEGG:04810 | 0.00175401113695 | 0.5 | NRAS KRAS HRAS | Regulation of actin cytoskeleton |
| HP:0000826 | 0.00176606420523 | 0.5 | NRAS KRAS HRAS | Precocious puberty |
| HP:0011004 | 0.00177010317298 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal systemic arterial morphology |
| KEGG:05205 | 0.0017821830589 | 0.5 | NRAS KRAS HRAS | Proteoglycans in cancer |
| KEGG:05203 | 0.0017821830589 | 0.5 | NRAS KRAS HRAS | Viral carcinogenesis |
| HP:0030448 | 0.00183201380014 | 0.5 | NRAS KRAS HRAS | Soft tissue sarcoma |
| HP:0009484 | 0.00183629101111 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Deviation of the hand or of fingers of the hand |
| HP:0100000 | 0.00189957809204 | 0.5 | NRAS KRAS HRAS | Early onset of sexual maturation |
| REAC:R-HSA-5621481 | 0.00190266482243 | 0.5 | NRAS KRAS HRAS | C-type lectin receptors (CLRs) |
| KEGG:05166 | 0.00204927990704 | 0.5 | NRAS KRAS HRAS | Human T-cell leukemia virus 1 infection |
| HP:0005523 | 0.00210158306671 | 0.333333333333 | NRAS KRAS | Lymphoproliferative disorder |
| KEGG:05170 | 0.00211201253822 | 0.5 | NRAS KRAS HRAS | Human immunodeficiency virus 1 infection |
| HP:0000766 | 0.00211964777507 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormality of the sternum |
| KEGG:05163 | 0.00220846662002 | 0.5 | NRAS KRAS HRAS | Human cytomegalovirus infection |
| REAC:R-HSA-416476 | 0.0022381799141 | 0.5 | NRAS KRAS HRAS | G alpha (q) signalling events |
| HP:0000293 | 0.00241935032153 | 0.5 | NRAS KRAS HRAS | Full cheeks |
| HP:0001974 | 0.00241935032153 | 0.5 | NRAS ABL1 KRAS | Leukocytosis |
| HP:0003745 | 0.00241935032153 | 0.5 | NRAS KRAS HRAS | Sporadic |
| KEGG:04714 | 0.00244472448991 | 0.5 | NRAS KRAS HRAS | Thermogenesis |
| WP:WP382 | 0.00250833969364 | 0.5 | NRAS KRAS HRAS | MAPK Signaling Pathway |
| HP:0001072 | 0.00251821780491 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Thickened skin |
| HP:0100568 | 0.00266824580105 | 0.5 | NRAS KRAS HRAS | Neoplasm of the endocrine system |
| HP:0012310 | 0.00270155144475 | 0.333333333333 | NRAS KRAS | Abnormal monocyte count |
| HP:0012144 | 0.00270155144475 | 0.333333333333 | NRAS KRAS | Abnormality monocyte morphology |
| HP:0000232 | 0.00302574748504 | 0.5 | NRAS ABHD5 HRAS | Everted lower lip vermilion |
| HP:0031654 | 0.00302574748504 | 0.5 | NRAS KRAS HRAS | Abnormal pulmonary valve physiology |
| HP:0003764 | 0.0032158301853 | 0.5 | NRAS KRAS HRAS | Nevus |
| REAC:R-HSA-422475 | 0.00323741737614 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Axon guidance |
| HP:0000418 | 0.00337633448894 | 0.333333333333 | NRAS HRAS | Narrow nasal ridge |
| HP:0002729 | 0.00337633448894 | 0.333333333333 | NRAS KRAS | Follicular hyperplasia |
| HP:0000324 | 0.00351554680502 | 0.5 | NRAS KRAS HRAS | Facial asymmetry |
| HP:0030962 | 0.0035891046318 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal morphology of the great vessels |
| HP:0010786 | 0.00361941962178 | 0.5 | NRAS KRAS HRAS | Urinary tract neoplasm |
| HP:0012472 | 0.00372530767778 | 0.5 | NRAS ABHD5 HRAS | Eclabion |
| HP:0002921 | 0.00373876477543 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormality of the cerebrospinal fluid |
| HP:0100242 | 0.00383322991569 | 0.5 | NRAS KRAS HRAS | Sarcoma |
| HP:0002514 | 0.00383322991569 | 0.5 | NRAS KRAS HRAS | Cerebral calcification |
| HP:0001028 | 0.00383322991569 | 0.5 | NRAS KRAS HRAS | Hemangioma |
| REAC:R-HSA-109582 | 0.00385038750362 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Hemostasis |
| HP:0004322 | 0.00392821369626 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Short stature |
| HP:0001305 | 0.00394320526633 | 0.5 | NRAS KRAS HRAS | Dandy-Walker malformation |
| WP:WP3932 | 0.00399196485232 | 0.5 | NRAS KRAS HRAS | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway |
| HP:0100742 | 0.00405525264868 | 0.5 | NRAS KRAS HRAS | Vascular neoplasm |
| HP:0005445 | 0.00405525264868 | 0.5 | NRAS KRAS HRAS | Widened posterior fossa |
| HP:0001627 | 0.00410936265542 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormal heart morphology |
| HP:0006731 | 0.00412589193299 | 0.333333333333 | NRAS HRAS | Follicular thyroid carcinoma |
| HP:0001638 | 0.00413322926791 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Cardiomyopathy |
| HP:0003422 | 0.00416939096982 | 0.5 | NRAS KRAS HRAS | Vertebral segmentation defect |
| HP:0000326 | 0.00440401599767 | 0.5 | NRAS ABL1 HRAS | Abnormality of the maxilla |
| KEGG:04010 | 0.0044724791401 | 0.5 | NRAS KRAS HRAS | MAPK signaling pathway |
| HP:0002757 | 0.00464723136975 | 0.5 | NRAS KRAS HRAS | Recurrent fractures |
| HP:0000098 | 0.00464723136975 | 0.5 | NRAS KRAS HRAS | Tall stature |
| HP:0000506 | 0.00464723136975 | 0.5 | NRAS KRAS HRAS | Telecanthus |
| HP:0010950 | 0.00489918791641 | 0.5 | NRAS KRAS HRAS | Abnormality of the fourth ventricle |
| HP:0002198 | 0.00489918791641 | 0.5 | NRAS KRAS HRAS | Dilated fourth ventricle |
| HP:0000768 | 0.00489918791641 | 0.5 | NRAS KRAS HRAS | Pectus carinatum |
| HP:0012056 | 0.00495018352279 | 0.333333333333 | NRAS HRAS | Cutaneous melanoma |
| HP:0001637 | 0.00501415242466 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormal myocardium morphology |
| HP:0002350 | 0.00502849121292 | 0.5 | NRAS KRAS HRAS | Cerebellar cyst |
| HP:0007400 | 0.00502849121292 | 0.5 | NRAS KRAS HRAS | Irregular hyperpigmentation |
| HP:0001315 | 0.00506157887206 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Reduced tendon reflexes |
| REAC:R-HSA-112314 | 0.00509397763734 | 0.5 | NRAS KRAS HRAS | Neurotransmitter receptors and postsynaptic signal transmission |
| HP:0001881 | 0.00515743219305 | 0.666666666667 | NRAS ABHD5 ABL1 KRAS | Abnormal leukocyte morphology |
| HP:0010987 | 0.00515743219305 | 0.666666666667 | NRAS ABHD5 ABL1 KRAS | Abnormal cellular immune system morphology |
| HP:0011772 | 0.00516003627866 | 0.5 | NRAS KRAS HRAS | Abnormality of thyroid morphology |
| HP:0000002 | 0.00549380780319 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of body height |
| WP:WP4172 | 0.00560540779735 | 0.5 | NRAS KRAS HRAS | PI3K-Akt Signaling Pathway |
| HP:0032251 | 0.00570898035154 | 0.666666666667 | NRAS ABHD5 ABL1 KRAS | Abnormal immune system morphology |
| HP:0001909 | 0.00570901006754 | 0.5 | NRAS ABL1 KRAS | Leukemia |
| HP:0000932 | 0.00570901006754 | 0.5 | NRAS KRAS HRAS | Abnormality of the posterior cranial fossa |
| HP:0100542 | 0.00614519903403 | 0.5 | NRAS KRAS HRAS | Abnormal localization of kidney |
| HP:0011381 | 0.00682280818411 | 0.333333333333 | NRAS KRAS | Aplasia of the semicircular canal |
| REAC:R-HSA-5673001 | 0.00693149789298 | 0.5 | NRAS KRAS HRAS | RAF/MAP kinase cascade |
| HP:0002693 | 0.0070826612539 | 0.5 | NRAS KRAS HRAS | Abnormality of the skull base |
| KEGG:04151 | 0.00716177546378 | 0.5 | NRAS KRAS HRAS | PI3K-Akt signaling pathway |
| HP:0000218 | 0.00731058822592 | 0.666666666667 | NRAS HRAS ABL1 KRAS | High palate |
| REAC:R-HSA-5684996 | 0.00747860177468 | 0.5 | NRAS KRAS HRAS | MAPK1/MAPK3 signaling |
| HP:0011362 | 0.00762839526375 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormal hair quantity |
| HP:0000612 | 0.00775746503096 | 0.5 | NRAS KRAS HRAS | Iris coloboma |
| HP:0012324 | 0.00787106080828 | 0.333333333333 | NRAS KRAS | Myeloid leukemia |
| HP:0100827 | 0.00787106080828 | 0.333333333333 | NRAS KRAS | Lymphocytosis |
| HP:0000179 | 0.0079325653925 | 0.5 | NRAS KRAS HRAS | Thick lower lip vermilion |
| HP:0002751 | 0.0079325653925 | 0.5 | NRAS KRAS HRAS | Kyphoscoliosis |
| HP:0002817 | 0.00802906529576 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of the upper limb |
| KEGG:05165 | 0.0080443443451 | 0.5 | NRAS KRAS HRAS | Human papillomavirus infection |
| REAC:R-HSA-8939211 | 0.00805345998455 | 0.5 | NRAS KRAS HRAS | ESR-mediated signaling |
| HP:0010719 | 0.00865912215453 | 0.5 | NRAS KRAS HRAS | Abnormality of hair texture |
| HP:0030724 | 0.0088473929681 | 0.5 | NRAS KRAS HRAS | Central nervous system cyst |
| HP:0010576 | 0.0088473929681 | 0.5 | NRAS KRAS HRAS | Intracranial cystic lesion |
| REAC:R-HSA-9607240 | 0.00890613892713 | 0.5 | NRAS KRAS HRAS | FLT3 Signaling |
| HP:0100702 | 0.00899388668352 | 0.333333333333 | NRAS KRAS | Arachnoid cyst |
| HP:0100700 | 0.00899388668352 | 0.333333333333 | NRAS KRAS | Abnormal arachnoid mater morphology |
| HP:0004375 | 0.00903835350739 | 0.5 | NRAS KRAS HRAS | Neoplasm of the nervous system |
| HP:0100763 | 0.0100697018086 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormality of the lymphatic system |
| HP:0010647 | 0.0106650876034 | 0.5 | HRAS ABL1 KRAS | Abnormal elasticity of skin |
| HP:0003271 | 0.0108869032108 | 0.666666666667 | NRAS ABHD5 ABL1 KRAS | Visceromegaly |
| REAC:R-HSA-449836 | 0.0110738408593 | 0.5 | NRAS KRAS HRAS | Other interleukin signaling |
| REAC:R-HSA-112315 | 0.0110738408593 | 0.5 | NRAS KRAS HRAS | Transmission across Chemical Synapses |
| HP:0007379 | 0.0110999618929 | 0.5 | NRAS KRAS HRAS | Neoplasm of the genitourinary tract |
| WP:WP2374 | 0.0111423482415 | 0.333333333333 | KRAS HRAS | Oncostatin M Signaling Pathway |
| HP:0000508 | 0.0112271947589 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Ptosis |
| HP:0008069 | 0.0113217289996 | 0.5 | NRAS KRAS HRAS | Neoplasm of the skin |
| HP:0030680 | 0.0114161328091 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of cardiovascular system morphology |
| HP:0011380 | 0.0114630974264 | 0.333333333333 | NRAS KRAS | Morphological abnormality of the semicircular canal |
| HP:0000377 | 0.0115753226372 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormality of the pinna |
| REAC:R-HSA-5683057 | 0.0124331344017 | 0.5 | NRAS KRAS HRAS | MAPK family signaling cascades |
| HP:0000028 | 0.0127622690023 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Cryptorchidism |
| HP:0006191 | 0.0128094019441 | 0.333333333333 | KRAS HRAS | Deep palmar crease |
| HP:0004426 | 0.0129566396101 | 0.5 | NRAS KRAS HRAS | Abnormality of the cheek |
| HP:0001010 | 0.0129566396101 | 0.5 | NRAS KRAS HRAS | Hypopigmentation of the skin |
| HP:0000606 | 0.0132022099229 | 0.5 | NRAS KRAS HRAS | Abnormality of the periorbital region |
| HP:0002659 | 0.0137025423856 | 0.5 | NRAS KRAS HRAS | Increased susceptibility to fractures |
| REAC:R-HSA-9006931 | 0.0137298534004 | 0.5 | NRAS KRAS HRAS | Signaling by Nuclear Receptors |
| HP:0001320 | 0.0139573410906 | 0.5 | NRAS KRAS HRAS | Cerebellar vermis hypoplasia |
| HP:0002859 | 0.0142301190129 | 0.333333333333 | NRAS HRAS | Rhabdomyosarcoma |
| HP:0001510 | 0.0145196622671 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Growth delay |
| HP:0005692 | 0.015007845 | 0.5 | NRAS KRAS HRAS | Joint hyperflexibility |
| HP:0001561 | 0.0152783894038 | 0.5 | NRAS KRAS HRAS | Polyhydramnios |
| HP:0010766 | 0.015552137599 | 0.5 | NRAS KRAS HRAS | Ectopic calcification |
| HP:0011376 | 0.0157252084881 | 0.333333333333 | NRAS KRAS | Morphological abnormality of the vestibule of the inner ear |
| HP:0001438 | 0.0158443316134 | 0.666666666667 | NRAS ABHD5 ABL1 KRAS | Abnormality of abdomen morphology |
| HP:0011805 | 0.0158498906484 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormal skeletal muscle morphology |
| HP:0001263 | 0.0162733566122 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Global developmental delay |
| HP:0006482 | 0.0166795319196 | 0.5 | NRAS KRAS HRAS | Abnormality of dental morphology |
| HP:0002715 | 0.0172110163622 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of the immune system |
| HP:0000938 | 0.0184698241162 | 0.5 | NRAS KRAS HRAS | Osteopenia |
| HP:0000589 | 0.0184698241162 | 0.5 | NRAS KRAS HRAS | Coloboma |
| HP:0000953 | 0.0187800119955 | 0.5 | NRAS KRAS HRAS | Hyperpigmentation of the skin |
| HP:0025015 | 0.0190617513532 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal vascular morphology |
| HP:0007477 | 0.0190936211778 | 0.5 | NRAS KRAS HRAS | Abnormal dermatoglyphics |
| HP:0006817 | 0.0200551569888 | 0.5 | NRAS KRAS HRAS | Aplasia/Hypoplasia of the cerebellar vermis |
| HP:0007957 | 0.0213861967068 | 0.5 | NRAS KRAS HRAS | Corneal opacity |
| HP:0011121 | 0.0218588319821 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of skin morphology |
| HP:0009728 | 0.0224484879882 | 0.333333333333 | NRAS HRAS | Neoplasm of striated muscle |
| HP:0002107 | 0.0224484879882 | 0.333333333333 | ABL1 HRAS | Pneumothorax |
| HP:0000368 | 0.0238534736244 | 0.5 | NRAS KRAS HRAS | Low-set, posteriorly rotated ears |
| HP:0000391 | 0.0243148377528 | 0.333333333333 | NRAS KRAS | Thickened helices |
| HP:0003111 | 0.0249658824542 | 0.5 | NRAS KRAS HRAS | Abnormal blood ion concentration |
| HP:0000568 | 0.0253441504586 | 0.5 | NRAS KRAS HRAS | Microphthalmia |
| HP:0004396 | 0.0262553193116 | 0.333333333333 | ABL1 KRAS | Poor appetite |
| HP:0011355 | 0.0264290937445 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Localized skin lesion |
| HP:0012471 | 0.0265015994402 | 0.5 | NRAS KRAS HRAS | Thick vermilion border |
| HP:0031816 | 0.027635799518 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormal oral morphology |
| HP:0000163 | 0.027635799518 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormal oral cavity morphology |
| HP:0011793 | 0.0279206634233 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Neoplasm by anatomical site |
| HP:0000602 | 0.0280983679133 | 0.5 | NRAS KRAS HRAS | Ophthalmoplegia |
| HP:0002334 | 0.0289200021372 | 0.5 | NRAS KRAS HRAS | Abnormality of the cerebellar vermis |
| HP:0000765 | 0.0289490814787 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormality of the thorax |
| REAC:R-HSA-168249 | 0.0291400473135 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Innate Immune System |
| HP:0004377 | 0.0297573256792 | 0.5 | NRAS ABL1 KRAS | Hematological neoplasm |
| HP:0000962 | 0.0310430385225 | 0.5 | NRAS KRAS HRAS | Hyperkeratosis |
| HP:0000164 | 0.0310897526003 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormality of the dentition |
| HP:0000951 | 0.0311492674319 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of the skin |
| HP:0001654 | 0.0314796075901 | 0.5 | NRAS KRAS HRAS | Abnormal heart valve morphology |
| REAC:R-HSA-1266738 | 0.0323042935377 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Developmental Biology |
| HP:0002664 | 0.0331529578102 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Neoplasm |
| HP:0001639 | 0.033266345548 | 0.5 | NRAS KRAS HRAS | Hypertrophic cardiomyopathy |
| HP:0000035 | 0.0333454168397 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal testis morphology |
| HP:0100887 | 0.0341842384581 | 0.5 | NRAS KRAS HRAS | Abnormality of globe size |
| HP:0001973 | 0.034757762481 | 0.333333333333 | NRAS KRAS | Autoimmune thrombocytopenia |
| HP:0100886 | 0.0353157942626 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormality of globe location |
| HP:0031653 | 0.0355921289237 | 0.5 | NRAS KRAS HRAS | Abnormal heart valve physiology |
| HP:0040006 | 0.0355921289237 | 0.5 | NRAS KRAS HRAS | Mortality/Aging |
| HP:0011420 | 0.0355921289237 | 0.5 | NRAS KRAS HRAS | Age of death |
| REAC:R-HSA-5663202 | 0.035783925956 | 0.5 | NRAS KRAS HRAS | Diseases of signal transduction |
| REAC:R-HSA-112316 | 0.0370544697669 | 0.5 | NRAS KRAS HRAS | Neuronal System |
| HP:0002890 | 0.0370683023611 | 0.333333333333 | NRAS HRAS | Thyroid carcinoma |
| HP:0000486 | 0.0371616198508 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Strabismus |
| HP:0000767 | 0.0375280162454 | 0.5 | NRAS ABL1 KRAS | Pectus excavatum |
| HP:0000153 | 0.0385037006662 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of the mouth |
| HP:0000597 | 0.0390245705401 | 0.5 | NRAS KRAS HRAS | Ophthalmoparesis |
| HP:0000290 | 0.0392952022063 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormality of the forehead |
| HP:0010318 | 0.0394527338604 | 0.333333333333 | NRAS KRAS | Aplasia/Hypoplasia of the abdominal wall musculature |
| HP:0008070 | 0.0395320179607 | 0.5 | NRAS KRAS HRAS | Sparse hair |
| HP:0030791 | 0.0403953252718 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal jaw morphology |
| HP:0012758 | 0.0404781039435 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Neurodevelopmental delay |
| HP:0001382 | 0.0410803928175 | 0.5 | NRAS KRAS HRAS | Joint hypermobility |
| HP:0040064 | 0.0417522324256 | 0.833333333333 | NRAS ABHD5 ABL1 HRAS KRAS | Abnormality of limbs |
| HP:0011792 | 0.0421345110279 | 0.5 | NRAS KRAS HRAS | Neoplasm by histology |
| HP:0000359 | 0.0422026822299 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormality of the inner ear |
| HP:0000549 | 0.0424327328427 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormal conjugate eye movement |
| HP:0000159 | 0.0426637093966 | 0.666666666667 | NRAS HRAS KRAS ABHD5 | Abnormal lip morphology |
| HP:0005105 | 0.0426637093966 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal nasal morphology |
| HP:0002088 | 0.0431284498901 | 0.666666666667 | NRAS HRAS ABL1 KRAS | Abnormal lung morphology |
| HP:0000476 | 0.044443111782 | 0.333333333333 | NRAS KRAS | Cystic hygroma |
| HP:0011357 | 0.0459638888097 | 0.5 | NRAS KRAS HRAS | Abnormality of hair density |
| HP:0002750 | 0.0465289476346 | 0.5 | NRAS KRAS HRAS | Delayed skeletal maturation |
| HP:0002815 | 0.0465289476346 | 0.5 | NRAS KRAS HRAS | Abnormality of the knee |
| HP:0011869 | 0.0470489782673 | 0.333333333333 | NRAS KRAS | Abnormal platelet function |
| WP:WP51 | 0.0472061557789 | 0.333333333333 | NRAS KRAS | Regulation of Actin Cytoskeleton |
| WP:WP4239 | 0.049358027697 | 0.333333333333 | KRAS HRAS | Epithelial to mesenchymal transition in colorectal cancer |
| HP:0007440 | 0.0497285764978 | 0.333333333333 | KRAS HRAS | Generalized hyperpigmentation |
| HP:0002002 | 0.0497285764978 | 0.333333333333 | NRAS HRAS | Deep philtrum |
| HP:0012740 | 0.0497285764978 | 0.333333333333 | NRAS HRAS | Papilloma |
| CORUM:5922 | 0.0499726005494 | 0.166666666667 | HRAS | RAF1-RAS complex, EGF induced |
| CORUM:2811 | 0.0499726005494 | 0.166666666667 | ABL1 | BRCA1-cABL complex |
Edges
| Protein 1 | Protein 2 | Score | Precision | Evidence |
|---|---|---|---|---|
| KRAS | RIN1 | 0.761 | 0.749 | bioplex (RIN1) bioplex_WMM |
| ABL1 | RIN1 | 0.288 | 0.489 | bioplex (RIN1) bioplex_WMM |
| RIN1 | NRAS | 0.159 | 0.418 | bioplex (RIN1) bioplex_WMM boldt (RIN1) boldt_WMM |
| RIN1 | HRAS | 0.056 | 0.313 | bioplex (RIN1) bioplex_WMM |
| NRAS | ABHD5 | 0.027 | 0.223 | bioplex (ABHD5) bioplex_WMM |
| KRAS | ABL1 | 0.008 | 0.085 | bioplex_WMM WMM_only |
| KRAS | HRAS | 0.008 | 0.065 | bioplex_WMM WMM_only |
| KRAS | NRAS | 0.007 | 0.01 | bioplex_WMM WMM_only |
| ABL1 | NRAS | 0.007 | 0.01 | bioplex_WMM WMM_only |
| ABL1 | HRAS | 0.007 | 0.002 | bioplex_WMM WMM_only |
| NRAS | HRAS | 0.006 | 0.004 | bioplex_WMM WMM_only boldt_WMM |
Images
Click to enlarge
Complex HuMAP2_03589 has an average edge precision of 0.215 which is ranked 5939 out of all 6965 complexes.
Related Complexes
| Genename | Complexes |
|---|---|
| ABL1 | HuMAP2_03589 HuMAP2_04499 |
| KRAS | HuMAP2_01070 HuMAP2_03589 HuMAP2_04499 HuMAP2_05327 |
| ABHD5 | HuMAP2_03589 HuMAP2_04467 |
| NRAS | HuMAP2_03589 HuMAP2_04467 HuMAP2_04499 |
| HRAS | HuMAP2_03589 HuMAP2_04499 |
| RIN1 | HuMAP2_03589 HuMAP2_04499 HuMAP2_05327 |